Japan’s Daiichi Sankyo Co is exploring the sale of its over-the-counter drugs (OTC) business and has hired JPMorgan to advise on the potential deal, several people with knowledge of the matter told Reuters.
Japan’s No.4 drugmaker by revenue has been focused on developing cancer treatments to offset a revenue drop following patent expirations of its mainstay high blood pressure drug.
